Group items matching

in title, tags, annotations or url

Transport wheelchairs are machines or equipment that facilitate for mobility and movement of wheelchair confined people at public places. While it is true that simple wheelchairs can do the trick, travel Wheelchair are specifically designed and manufactured to facilitate better roaming and mobility at malls, restaurants and parks where people usually converge to relax. A seat belt and swing-away removable footrests are standard and make it easy to get in and out of this chair. A fold-down back allows for easier storage and transport and padded armrests add additional comfort. The materials with which travel Wheelchair are made are of more superior quality and strength. That is because Travel Wheelchair are made very specifically to facilitate movement at public and outdoor places. Also, travel Wheelchair are made of materials that are highly durable to enable it to carry out its purpose. Thus, it is often that users complain about the limited usefulness and comfort of using the wheelchairs. Karma Travel Wheelchair KM TV 20.2: Karma Travel Wheelchair KM TV 20.2 - 606 T-6 aircraft-grade aluminum-alloy frame provides incredible strength. Easy-to-fold in three seconds. Karma Travel Wheelchair KM TV 20.2 Features: Type: Travel Wheelchair T-6 aircraft-grade aluminum Secure brake improve safety Padded flip back armrest PU front caster & rear wheel Karma Travel Wheelchair KM TV 20.2 Measurements: Weight: 8.9kg Seat width: 39.5cm Tyre: PU front casters and rear wheels Capacity: 100kg Folded size: (L/W/H): 610mm x 350mm x710mm. Ultra Lightweight Wheelchair: Its compact design and feather light weight makes it suitable for people on the go. Ultra Lightweight Wheelchair Specifications: Frame Style : Foldable Frame Material : Aluminium (Light weight) Rear wheel to wheel width in open position (inches) : 20" Handle to Handle : 16" Seat Width (inches): 13" Rear Wheel Size: 7" Front Wheel Size: 5" Seat to floor height (inches): 19" Seat Dep

Lightweight Transport wheelchair is one of the the lightest transport chairs on the market, weighing in at only 19 lbs! With four great colors to choose from, it can be transported in style. A seat belt and swing-away removable footrests are standard and make it easy to get in and out of this chair. A fold-down back allows for easier storage and transport and padded armrests add additional comfort. It is made out of a lightweight and durable powder coated aluminum frame that is available in either red or blue. It is available in a 19" wide seat with permanent full-length arms and swing-away detachable footrests. The chair also has padded armrests and a seatbelt for safety purposes. Karma Travel Wheelchair KM TV 20.2 Karma Travel Wheelchair KM TV 20.2 - 606 T-6 aircraft-grade aluminum-alloy frame provides incredible strength. Easy-to-fold in three seconds. Karma Travel Wheelchair KM TV 20.2 Features Type: Travel Wheelchair T-6 aircraft-grade aluminum Secure brake improve safety Padded flip back armrest PU front caster & rear wheel Karma Travel Wheelchair KM TV 20.2 Measurements Weight: 8.9kg Seat width: 39.5cm Tyre: PU front casters and rear wheels Capacity: 100kg Folded size: (L/W/H): 610mm x 350mm x710mm. Ultra Lightweight Wheelchair Its compact design and feather light weight makes it suitable for people on the go. Ultra Lightweight Wheelchair Specifications Frame Style : Foldable Frame Material : Aluminium (Light weight) Rear wheel to wheel width in open position (inches) : 20" Handle to Handle : 16" Seat Width (inches): 13" Rear Wheel Size: 7" Front Wheel Size: 5" Seat to floor height (inches): 19" Seat Depth (inches): 13" Back height (inches): 16" Total height (inches): 35" Max User Weight Capacity (kgs): 80 k.g. Net Weight (kgs): 8.5 k.g. Upholstery: Cloth look like, washable Armrest: Flip up, for easy transfer to bed Legrest: Flip up footplate Wheel Quality: Tear resistant polyurethane wheels Rear Wheel Lo

Transport chairs make it easier for loved ones and caregivers to help get around in comfort and ease. Compared to a standard wheelchair, a transport chair requires a caregiver to push the chair. A transport chair is much lighter than a wheelchair; plus, it is more compact which makes getting around town easier. This chair comes equipped with loop-lock hand brakes that are easy to operate and ideal for locking the rear wheels during transfers. It also has a seatbelt which keeps the passenger securely in place and it is compact when folded making it easy to lift into a car or carry up the stairs. Weighs just 23.5 lbs and is equipped with a seat belt, comfortable nylon upholstery, full length permanent armrest, and detachable footrests. It has a 19 inch wide seat that can provide and a weight capacity of 300 pounds. This wheelchair can be used both indoors and outdoors on forgiving terrain, with a convenient step for the attendant to lift the chair over obstacles. This transport wheelchair gives the freedom to go, with the added convenience of folding up to a manageable size. Karma Travel Wheelchair KM TV 20.2 Karma Travel Wheelchair KM TV 20.2 - 606 T-6 aircraft-grade aluminum-alloy frame provides incredible strength. Easy-to-fold in three seconds. Karma Travel Wheelchair KM TV 20.2 Features Type: Travel Wheelchair T-6 aircraft-grade aluminum Secure brake improve safety Padded flip back armrest PU front caster & rear wheel Karma Travel Wheelchair KM TV 20.2 Measurements Weight: 8.9kg Seat width: 39.5cm Tyre: PU front casters and rear wheels Capacity: 100kg Folded size: (L/W/H): 610mm x 350mm x710mm. Ultra Lightweight Wheelchair Its compact design and feather light weight makes it suitable for people on the go. Ultra Lightweight Wheelchair Specifications Frame Style : Foldable Frame Material : Aluminium (Light weight) Rear wheel to wheel width in open position (inches) : 20" Handle to Handle : 16" Seat Width (inches): 13" Rear Whee

Transport wheelchairs or companion chairs are companion wheelchairs where the purpose is for a companion to push the user. Most of our transporters have swing-away leg rests, fixed armrests, and side panels. Instead of the usual 'large back - small front' wheels typical of most wheelchairs, light travel chairs have four small wheels providing much easier maneuverability of the chair. It is easily transportable and comes with a compact carry bag, making it ideal for stowing away in cars, buses, trains, and more. This wheelchair can be used both indoors and outdoors on forgiving terrain, with a convenient step for the attendant to lift the chair over obstacles. This transport chair gives the freedom to go, with the added convenience of folding up to a manageable size. Karma Travel Wheelchair KM TV 20.2 Karma Travel Wheelchair KM TV 20.2 - 606 T-6 aircraft-grade aluminum-alloy frame provides incredible strength. Easy-to-fold in three seconds. Karma Travel Wheelchair KM TV 20.2 Features Type: Travel Wheelchair T-6 aircraft-grade aluminum Secure brake improve safety Padded flip back armrest PU front caster & rear wheel Karma Travel Wheelchair KM TV 20.2 Measurements Weight: 8.9kg Seat width: 39.5cm Tyre: PU front casters and rear wheels Capacity: 100kg Folded size: (L/W/H): 610mm x 350mm x710mm. Ultra Lightweight Wheelchair Its compact design and feather light weight makes it suitable for people on the go. Ultra Lightweight Wheelchair Specifications Frame Style : Foldable Frame Material : Aluminium (Light weight) Rear wheel to wheel width in open position (inches) : 20" Handle to Handle : 16" Seat Width (inches): 13" Rear Wheel Size: 7" Front Wheel Size: 5" Seat to floor height (inches): 19" Seat Depth (inches): 13" Back height (inches): 16" Total height (inches): 35" Max User Weight Capacity (kgs): 80 k.g. Net Weight (kgs): 8.5 k.g. Upholstery: Cloth look like, washable Armrest: Flip up, for easy transfer to bed Legr

A cancer registry is the cancer cases which are registered in a population or specific country. In whole world mortality rate due to cancer is 20%. In USA cancer is the second largest disease of causing death after heart disease. Recently in 2016 estimated that 595,690 people die from this disease according to cancer statistics of National Cancer Institute USA.

Are you looking at reclaiming that lean and healthy body you once had even as you leave your 40s and move into your 50s and 60s? Are you looking for a weight loss program that is proven to help lose weight? Have you heard about eat sleep burn diet by Dan Garner and you want a second thought on it before you purchase? Continue to read this eat sleep burn diet review. Is eat burn sleep recipe really a method to lose weight naturally and safely while you instantly start reversing health problems and practically double your energy overnight? ...click link for more

This full body shaper will firmly shape and give you the compression you need after lipo, tummy tuck or any plastic surgery procedure. This is a Stage 2 Post op Faja Enjoy top to bottom slimming in this full body girdle, This comfortable braless girlde gives you a slim and smooth silhouette for anytime you wan to look your best or after post surgical procedure. Plus is adds a plus it enhances your buttocks with a silk comfortable built in butt enhancer. Cold firming lycra material inside with high compression powernet long -leg girdle helps smooth your figure while adding everyday comfort, Slimming your thighs and helping compress bulges and help your legs look leaner. This body shaping compression garment has a zipper down the middle for easy adjusting with hooks on the inside with open crotch area for easy bathroom use. This is the second stage girdle you will need after any surgery it covers all areas and gives you maximum compression. RESULTS Full-body slimming enhances your silhouette Appearance of firmer, smoother midsection Smooths and slim your legs Adds volume and shape to your booty

Britain's booster programme for Covid-19 vaccinations is set to be expanded following advice from scientists. The government's Joint Committee on Vaccination and Immunisation (JCVI) said today (November 15) that all healthy adults aged 40-49 should be offered a booster, six months after their second dose. Previously, the booster programme was limited to those aged 50 and over, and the clinically vulnerable. So far, some 12.6 million people have had a booster dose. The latest advice comes after the UK Health Security Agency released data from a real-world study which found the booster gave over 90 per cent protection against symptomatic Covid-19 for people aged 50 years and older.

As the deadline for the frontline healthcare workers to get fully vaccinated approaches, tens of thousands of NHS staff who have not yet taken the Covid-19 vaccine face termination in just a fortnight. Although it is estimated that the majority of NHS staff have been fully jabbed, health and social care providers in England will soon be needed to ensure that all those working in areas regulated by the Care Quality Commission (CQC), are fully vaccinated against Covid-19 before the April 1, 2022. Those who are exempted from taking the vaccination do not fall under this purview. According to the NHS England guidance around Vaccination as a Condition of Deployment (VCOD) for healthcare workers, all frontline staff must have had both the doses by April 1, meaning that by February 3 the first must have been administered and the second by March 31. All unvaccinated frontline workers will be called into formal meetings from February 4 and given a warning of dismissal. Notices will then be issued from that day, with March 31 marking the end of the notice period

The government has launched a new campaign over social media and radio today (January 10) to encourage pregnant women to take their first, second and third dose of Covid-19 vaccine. Joined by experts at the Royal College of Obstetricians and Gynaecologists (RCOG) and the Royal College of Midwives (RCM), the campaign highlights the risks of the infection and benefits of vaccination. According to the latest data from the UK Health Security Agency (UKHSA), Covid-19 vaccinations are safe for pregnant women. Department of Health and Social Care (DHSC) chief scientific adviser professor Lucy Chappell, said: "We have extensive evidence now to show that the vaccines are safe and that the risks posed by Covid-19 are far greater," calling upon pregnant women who have yet to have their jabs. The campaign will also run testimonies of pregnant women who have had their jabs.

Professor Sir Jonathan Van-Tam has announced that he will step down as deputy chief medical officer (DCMO) for England at the end of March to take up a new role at the University of Nottingham. He joined Department of Health and Social Care (DHSC) on secondment from the university in 2017, and will soon return to be the pro-vice-chancellor for Faculty of Medicine and Health Sciences. Professor Van-Tam said: "My time as DCMO have been the most challenging of my professional career, especially the Covid response. We all wish Covid had never happened. Notwithstanding, it has been the greatest privilege of my professional career to have served the people of the UK during this time. "I want to pay tribute to Professor Chris Whitty, the CMO team, my fellow scientists, public health professionals and clinicians whose support, wisdom and energy has been inspiring. "I will continue to work until the end of March and look forward to the next challenge." As the DCMO for Health Protection, he has played key roles in various incidents, including domestic outbreaks of MERS and monkeypox, 2017 to 2018 influenza season and during the Covid-19 pandemic.

Nearly half of Type 1 diabetes patients in the NHS England are benefiting from the use of flash monitors that allow them to check their glucose levels more easily and regularly. The wearable gadget, linked with a phone app, has a sensor that attaches to the back of the arm, allowing patients to check their glucose with a simple one-second scan. Eligible patients can access the monitors on prescription from their local GP or diabetes team. The NHS is ahead of target to roll-out the monitors, as the independent health advisory NICE, confirmed it was beginning the consultation to expand the kit's access. As per recent data, around 125,000 patients now uses these monitors to help control their condition. The latest number shows that the NHS significantly exceeded its user target with more than 45 per cent of patients using the monitor.

'Tepotinib' has been recommended by the National Institute for Health and Care Excellence (NICE) to patients with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC). The new potentially life-extending drug is available from Thursday (14 April). It has been recommended for routine use across the NHS in England through Project Orbis, a programme to review and approve promising cancer drugs helping patients access treatments faster. NICE has published its final appraisal document recommending tepotinib (also known as Tepmetko and produced by company Merck Serono Ltd) as an option for treating advanced NSCLC with METex14 skipping gene alterations in adults. People with METex14 skipping alterations of NSCLC make up between 1-2% of all adults with lung cancer in England. Tepotinib, which requires people to take two tablets once daily, provides a new targeted treatment for adults with METex14 skipping gene alterations. Just over 700 people in England would be eligible to receive tepotinib as either a first or second-line treatment.

The Royal Pharmaceutical Society and Scottish Academy of Medical Royal Colleges co-hosted the NHS Education for Scotland annual virtual conference to discuss the environmental impact of prescribing. One of the conclusions drawn from the conference on Thursday (April 28) stressed on environmentally sustainable prescribing should be embedded in undergraduate and postgraduate health care education. Delegates at the session said they or their teams needed more education. They also needed more information and resources when prescribing to be able to consider environmental issues. Sharon Pfleger, Consultant in Pharmaceutical Public Health at NHS Highland, told the session: "There's a lot of work to be done to reduce carbon emissions. The NHS has identified the use of metered-dose inhalers as its second biggest cause of carbon emissions as the propellant gases have significant global warming potential.

The Fitness-to-Practise Committee of the General Pharmaceutical Council has issued a three-month suspension to Mohammed Roohul Haque (Reg No: 2226084), a locum pharmacist, due to incidents of workplace sexual misconduct. According to the determination document issued by the regulatory body, Haque undertook the position of a locum pharmacist at Hollowood Chemists on July 12. It was during this period that he encountered the dispenser (referred to as the "complainant"), a 40-year-old co-worker at the pharmacy, for the first instance. Following this initial meeting, he proceeded to engage in making explicit sexual comments. During the lunch break of the pharmacy's second dispenser, Haque asked the dispenser, who had lodged the complaint, to review photographs displayed on his mobile phone, depicting renovations being carried out at his residence. The initial images focused on the ongoing renovation activities. However, he later switched to displaying a full-screen photograph of his erect penis, the document said. Despite the fact that the dispenser promptly distanced herself, Haque persisted in discussing the photograph with her. He went so far as to apologise, and even asked if she had managed to closely observe the picture.

Wegovy maker Novo Nordisk said on Tuesday (Aug 8) a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit, boosting the Danish company's hopes of moving beyond its image as a lifestyle drug. The increasingly popular Wegovy has transformed the weight-loss market since its U.S. launch in June 2021, capturing the attention of patients, investors and celebrities worldwide. Novo's news lifted shares in Europe's second-most valuable listed company after LVMH by more than 17 per cent to record highs. They have now surged almost 165 per cent over the past two years. The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is $1,300 a month in the United States, for a wider range of patients. U.S. law classifies weight-loss treatments as lifestyle drugs and bars the Medicare health plan for older Americans from covering them and experts said the new data could lead the U.S. government to reassess that.

The Royal Pharmaceutical Society (RPS) Assembly has announced the re-appointment of Professor Claire Anderson as President for a further term of two years on Tuesday (11 July). As president, Anderson will oversee delivery and implementation of the constitutional governance review; continue to extend the profile and influence of pharmacy as a profession by building and strengthening relationships with all the other pharmacy leadership bodies and organisations. She aims to ensure that RPS is invited to the table whenever medicines and public health are discussed by continuing to invest in strategic relationships beyond pharmacy Claire was first elected as President in 2021. In her address to the Assembly, Claire said: "This is a time of unprecedented change and I have decided to stand as President for a second term to offer much needed continuity. "I am passionate about our profession and committed to making the RPS and our members even more successful. I will also continue to be a dedicated ambassador and advocate for the profession nationally and internationally."

Today, pharmaceutical companies can't simply make an effective drug and count on healthcare providers (HCPs) to come to them - they have to find innovative ways to attract them. Statista shows that in 2015 there were only 3,286 pharma companies with active research and development pipelines. In 2023, this number jumped to more than 5,500. As an earth-shattering number of new drugs are flooding the market each year, HCPs are having a hard time determining the best medicine for their patients. Meanwhile, pharma companies invest more in marketing to help HCPs get rid of choice paralysis and make them choose their solution over that of competitors. In this article, we will share the tried-and-true tactics to build a strong pharma brand. Get creative with interactive email marketing One…two…three…No, we're not counting to run a marathon. Three seconds is what you've got to pull your reader in with your email. Fail to quickly grab the audience's attention? We've got some bad news for you. Nobody's going to bother reading about how amazing your pharmaceutical product is if you're churning out generic emails with artificial intelligence tools.

NHS England has urged the pharmacy owners to continue to voluntarily submit New Medicine Service (NMS) quarterly summary data to the NHS Business Services Authority (NHSBSA) for Quarter 4 (Q4) 2022/23 (January to March 2023). Community Pharmacy England have agreed with NHS England that the quarterly returns will continue to be on a voluntary basis, with Q4 (January to March 2023) as the second quarter to be reported. It has thanked all the members that submitted NMS quarterly summary data for Quarter 3. The mandatory requirement to submit this data has been suspended since 2020, due to the COVID-19 pandemic. "NHS England wants to continue collection of the quarterly returns to provide baseline data to support a long-term evaluation that will be conducted as part of ongoing work to expand the scope of NMS," said Community Pharmacy England. Voluntary submissions can be made via the NHSBSA website, where an updated reporting spreadsheet is also available for head offices to use who are able to submit data on behalf of multiple pharmacies.